Taligen Therapeutics raises $65,000,000

Taligen Therapeutics, Inc. today announced it anticipates receiving up to $65 million in a tranched Series B financing.  Founded in 2004, Taligen Therapeutics, Inc. is a development-stage biotechnology company with novel technology and expertise focused on modulation and control of the complement system. The complement system is believed to be a critical component in the initiation of inflammation. Complement system activation is characteristic of many human diseases, including asthma, macular degeneration, rheumatoid arthritis and immune renal disease.